 Partial Response (irPR): Decrease in SPD of 50% or greater by a consecutive assessment at least 4 weeks after first documentation.  Stable Disease (irSD): Failure to meet criteria for irCR or irPR, in absence of irPD.  Progressive Disease (irPD): At least 25% increase in SPD relative to nadir (minimum recorded tumor burden) Conf irmation by a repeat, consecutive assessment no less than 4 weeks from the data first documented. Please note other key differences between irRC and the original WHO criteria: New measurable lesions will be incorporated into the SPD New non measurable lesions do not de fine progression but preclude irCR Non-index lesions contribute to defining irCR (complete disappearance required). See the Investigators Imaging Operations Manual (IIOM) for more details. REFERENCE IrRC for the current protocol is a dopted from the following reference: Wolchok, JD, Hoos, A, O’Day S, et al., Guide lines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Res ponse Criteria. Clinical Cancer Research, 2009 Dec 1;15(23):7412-20.